An overview of targeted alpha therapy with 225Actinium and 213Bismuth

Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy. This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.

Current radiopharmaceuticals. 2018 May 01 [Epub ahead of print]

Alfred Morgenstern, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki, Frank Bruchertseifer

European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe. Germany., Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg. Germany., Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria. South Africa., Department of Nuclear Medicine, Medical University Warsaw, Warsaw. Poland.

email news signup